Abstract
In the human risk assessment by physiologically based pharmacokinetic modeling (PBPK), verification of the modeling strategy and confirmation of the reliability of the output data are important when the clinical data are not available. A new herbicide, epyrifenacil, is metabolized to S-3100-CA in mammals and causes hepatotoxicity in mice. S-3100-CA is transferred to the liver by transporters and eliminated by biliary excretion and metabolism. In the previous human PBPK research, we succeeded in predicting S-3100-CA pharmacokinetics by obtaining human hepatic parameters from chimeric mice with humanized liver after we checked the model's quantitative performance using mouse experimental data. To further enhance the reliability of human PBPK data, verification of the following two points was considered effective: 1) verification of model applicability to pharmacokinetics prediction in multiple animal species, and 2) verification of the parameter acquisition methods. In this study, we applied the same modeling strategy to rats, i.e., we obtained rat hepatic parameters for PBPK from chimeric mice with rat hepatocytes, not from rats. As the simulation results, rat internal dosimetry was precisely reproduced, although it tended to be slightly overestimated by approximately two times. From the results of the sensitivity analysis, this overestimation was mainly due to hepatic parameters from chimeric mice. Therefore, it is suggested that a similar slight prediction error may occur also in human PBPK using chimeric mice, but considering the degree of error, it can be said that our modeling strategy is robust and the predicted human internal dosimetry in the previous research is reliable.
Keywords: Chimeric Mice with Rat Hepatocytes; Epyrifenacil; Model Applicability; Modeling Strategy; PBPK; Reliability of Human PBPK Data.
https://pubmed.ncbi.nlm.nih.gov/36858113/ Toxicol Appl Pharmacol. 2023 Feb 27;465:116439 Kota Hirasawa, Jun Abe, Hirohisa Nagahori, Sachiko Kitamoto
Abstract In the human risk assessment by physiologically based pharmacokinetic modeling (PBPK), verification of the modeling strategy and confirmation of the reliability of the output data are important when the clinical data are not available. A new herbicide, epyrifenacil, is metabolized to S-3100-CA in mammals and causes hepatotoxicity in mice. S-3100-CA is transferred to the liver by transporters and eliminated by biliary excretion and metabolism. In the previous human PBPK research, we succeeded in predicting S-3100-CA pharmacokinetics by obtaining human hepatic parameters from chimeric mice with humanized liver after we checked the model's quantitative performance using mouse experimental data. To further enhance the reliability of human PBPK data, verification of the following two points was considered effective: 1) verification of model applicability to pharmacokinetics prediction in multiple animal species, and 2) verification of the parameter acquisition methods. In this study, we applied the same modeling strategy to rats, i.e., we obtained rat hepatic parameters for PBPK from chimeric mice with rat hepatocytes, not from rats. As the simulation results, rat internal dosimetry was precisely reproduced, although it tended to be slightly overestimated by approximately two times. From the results of the sensitivity analysis, this overestimation was mainly due to hepatic parameters from chimeric mice. Therefore, it is suggested that a similar slight prediction error may occur also in human PBPK using chimeric mice, but considering the degree of error, it can be said that our modeling strategy is robust and the predicted human internal dosimetry in the previous research is reliable.
Keywords: Chimeric Mice with Rat Hepatocytes; Epyrifenacil; Model Applicability; Modeling Strategy; PBPK; Reliability of Human PBPK Data.